StockData
EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Edgewise Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$37.92+0.73 (+1.96%)

Close on Oct 19, 2026

Market cap
$4.08B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 6, 2026Before market open–––
Q1 FY2026
Ended Mar 31, 2026
May 7, 2026Before market open–$-0.46–
Q4 FY2025
Ended Dec 31, 2025
Feb 26, 2026Before market open–$-0.47–
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025Before market open–$-0.39–
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025Before market open–$-0.34–
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025Before market open–$-0.43–
Q4 FY2024
Ended Dec 31, 2024
Mar 3, 2025Before market open–$-0.42–
Q3 FY2024
Ended Sep 30, 2024
Nov 7, 2024Before market open–––
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024Before market open–––
Q1 FY2024
Ended Mar 31, 2024
May 9, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Feb 22, 2024Before market open–––

Press releases

Announcements Edgewise Therapeutics filed with the SEC